Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Oct;6(5):626-629.
doi: 10.3748/wjg.v6.i5.626.

Design, delivery and efficacy testing of therapeutic nucleic acidsused to inhibit hepatitis C virus gene expression in vitro and in vivo

Wolfgang H Caselmann, Matthias Serwe, Thomas Lehmann, Jnos Ludwig, Brian S Sproat, Joachim W Engels

Design, delivery and efficacy testing of therapeutic nucleic acidsused to inhibit hepatitis C virus gene expression in vitro and in vivo

Wolfgang H Caselmann et al. World J Gastroenterol. 2000 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
HCV 5’-non-coding region. The pseudonot region and stem loop IV including the start AUG are indicated in bold font as optimum target sequences for ODN binding.
Figure 2
Figure 2
Plasmid constructs to analyze inhibition of HCV translation in vitro (upper) and in vivo (lower). Expression is directed either by the T7-promoter or the CMV immediate early promoter.
Figure 3
Figure 3
Modified hammerhead RZ and HCV target sequence. The G16.2,C16.1, A17 recognition site (nts. 346-348), in which cleavage occurs, is marked by an arrow. All nucleotides are 2’-O-ally l-ribonucleotides except G5, A6, G8 and G12 (light gray), which are unmodified ribonucleotides. The position of the A to l exchange (medium gray) and the start AUG of the HCV template are indicated.
Figure 4
Figure 4
Schematic representation of a taurocholic acid-coupled antisense oligodeoxynucleotide. R: oligodeoxynucleotide 5’-end.
See this image and copyright information in PMC

References

    1. Wedemeyer H, Caselmann WH, Manns MP. Combination therapy of chronic hepatitis C: an important step but not the final goal! J Hepatol. 1998;29:1010–1014. - PubMed
    1. Varaklioti A, Georgopoulou U, Kakkanas A, Psaridi L, Serwe M, Caselmann WH, Mavromara P. Mutational analysis of two unstructured domains of the 5' untranslated region of HCV RNA. Biochem Biophys Res Commun. 1998;253:678–685. - PubMed
    1. Alt M, Renz R, Hofschneider PH, Caselmann WH. Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhibitors of hepatitis C viral translation. Arch Virol. 1997;142:589–599. - PubMed
    1. Alt M, Renz R, Hofschneider PH, Paumgartner G, Caselmann WH. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides. Hepatology. 1995;22:707–717. - PubMed
    1. Alt M, Eisenhardt S, Serwe M, Renz R, Engels JW, Caselmann WH. Comparative inhibitory potential of differently modified antisense oligodeoxynucleotides on hepatitis C virus translation. Eur J Clin Invest. 1999;29:868–876. - PubMed